TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03379181
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive a single dose of 80 mg propranolol p.o.
Study: NCT01310777
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01310777
Drug: Brinzolamide 1% ophthalmic suspension
Normalized name: Brinzolamide 1% Ophthalmic Suspension
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01310777
Drug: Brimonidine tartrate 0.2% ophthalmic solution
Normalized name: Brimonidine Tartrate 0.2% Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02203396
Drug: rabbit ATG, Cyclosporine, Levamisole
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
Study: NCT04623931
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03774732
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity
Study: NCT01350947
Drug: 5-Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes.
Study: NCT03365882
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03781986
Drug: APG-115
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
Study: NCT03781986
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
Study: NCT03932344
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra according to prescription
Study: NCT03939624
Drug: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
Normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
Study: NCT03939624
Drug: Dipeptidyl peptidase-4 (DPP-4) inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
Study: NCT04418024
Drug: AG10
Normalized name: JAG101
DrugBank: JAG101 (DB18321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTR stabilizer administered orally twice daily (BID)
Study: NCT02435212
Drug: Deferasirox granule formulation
Normalized name: deferasirox Granule Product
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use and will be administered based on body weight.
Study: NCT02435212
Drug: Deferasirox DT formulation
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use and will be administered based on body weight.
Study: NCT01856270
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
Study: NCT02731638
Drug: Intrastromal voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
Study: NCT02731638
Drug: Natamycin
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive topical 5% natamycin drops hourly for 3 days.
Study: NCT03169777
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03169777
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
Study: NCT03169777
Drug: nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study: NCT03169777
Drug: Lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3-acid ethyl esters
Study: NCT03169777
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study: NCT03538041
Drug: Parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib administered orally.
Study: NCT00000211
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04439539
Drug: JNJ-73763989
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-73763989 injection will be administered subcutaneously.
Study: NCT04439539
Drug: PegIFN-alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN-alpha-2a injection will be administered subcutaneously.
Study: NCT04439539
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil film-coated tablet will be administered orally.
Study: NCT04439539
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide film-coated tablet will be administered orally.
Study: NCT04439539
Drug: JNJ-56136379
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 will be administered orally.
Study: NCT00336063
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT00336063
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00250042
Drug: Gleevec and Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pts. who fit the inclusion criteria, \& were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) \& then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
Study: NCT04111458
Drug: BI 1701963
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04111458
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT02227914
Drug: Oprozomib
Normalized name: Oprozomib
DrugBank: Oprozomib (DB11991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
Study: NCT02227914
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study subjects will receive sorafenib tablets twice a day for Days 1-28
Study: NCT00611936
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg maximum of d-amphetamine
Study: NCT04160117
Drug: Colchicine 0.6 mg
Normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
Study: NCT04439227
Drug: Adavosertib
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02226341
Drug: CellCept
Normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144
Study: NCT02226341
Drug: ACTHar gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
Study: NCT03285321
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 480mg
Study: NCT03285321
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240mg
Study: NCT03285321
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1mg/kg
Study: NCT02122562
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment
Study: NCT04298697
Drug: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
Study: NCT04268888
Drug: Nivolumab and TACE/TAE
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunotherapy and TACE/TAE
Study: NCT02673372
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
Study: NCT02673372
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
Study: NCT00392353
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT00392353
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04263623
Drug: Dexmecamylamine HCl
Normalized name: Mecamylamine Hydrochloride
DrugBank: Dexmecamylamine (DB11807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT03107988
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
Study: NCT03107988
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle
Study: NCT03107988
Drug: Filgrastim/pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Filgrastim is to be given with each course beginning 24-48 hours following completion of cyclophosphamide and topotecan and continued through post-nadir count recovery with an ANC \> 2000/mm\^3 at 5mcg/kg/day. Filgrastim must be discontinued at least 24 hours prior to the start of the next course of therapy.~Pegfilgrastim (100mcg/kg; 6mg maximum dose) may be substituted and is given one time at 24-48 hours from completion of cyclophosphamide and topotecan.
Study: NCT00352768
Drug: Fluvoxamine maleate
Normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
Study: NCT02780128
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
Study: NCT02780128
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
Study: NCT01105429
Drug: BMS-820132
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 0.3 mg, once daily, 1 day
Study: NCT01105429
Drug: BMS-820132
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 1.0 mg, once daily, 1 day
Study: NCT01105429
Drug: BMS-820132
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 3 mg, once daily, 1 day
Study: NCT01105429
Drug: BMS-820132
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 10 mg, once daily, 1 day
Study: NCT01498068
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
Study: NCT01105429
Drug: BMS-820132
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 30 mg, once daily, 1 day
Study: NCT01105429
Drug: BMS-820132
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral , 75 mg, once daily, 1 day
Study: NCT01498068
Drug: Pegylated-interferon-alfa-2a
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
Study: NCT01498068
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.
Study: NCT01054014
Drug: JNJ-40346527/Placebo
DrugBank: JNJ-40346527 (DB12504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
Study: NCT01054014
Drug: JNJ-40346527/Placebo
DrugBank: JNJ-40346527 (DB12504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
Study: NCT01054014
Drug: JNJ-40346527
Normalized name: JNJ-40346527
DrugBank: JNJ-40346527 (DB12504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
Study: NCT02474316
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
Study: NCT02474316
Drug: nucleos(t)ide analgoue
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
Study: NCT01855529
Drug: Ropivacaine in one arm and placebo (NaCl) in the other arm
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00549146
Drug: fluticasone propionate/salmeterol 250/50 DISKUS combination product
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00549146
Drug: fluticasone propionate DISKUS 500mcg
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01521117
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
Study: NCT01105429
Drug: BMS-820132
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 150 mg, once daily, 1 day
Study: NCT01105429
Drug: BMS-820132
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 300 mg, once daily, 1 day
Study: NCT03361800
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral drug, 5mg tablet given once weekly x 2 doses
Study: NCT03923166
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg qd
Study: NCT01105429
Drug: BMS-820132
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, Oral, (TBD), once daily, 2 days
Study: NCT00771758
Drug: oxycodone IR
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maximum daily dose 450 mg
Study: NCT00771758
Drug: tapentadol IR
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
Study: NCT04065269
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATR inhibitor
Study: NCT04065269
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PARP inhibitor
Study: NCT04065269
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PD-L1 immunotherapy
Study: NCT04432584
Drug: Crovalimab
Normalized name: Crovalimab
DrugBank: Crovalimab (DB16128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight \>=100kg). Dosing schedule will be as described above.
Study: NCT04432584
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eculizumab will be administered at a dose of 900 mg every 2 weeks, as per the dosing schedule described above.
Study: NCT00522093
Drug: TJ-100
Normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-100 2.5g three times per day for 6 weeks
Study: NCT03534804
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib is administered at 40 mg oral daily
Study: NCT03534804
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.